One-year results of verteporfin therapy for subretinal neovascularization associated with type 2A parafoveal telengiectasia

BACKGROUND: To report the 12 months follow up results of verteporfin therapy for subretinal neovascularization (SRNV) associated with type 2A parafoveal telangiectasia (PFT). METHODS: A Prospective interventional case series. Patients who completed 12 months follow up following photodynamic dynamic therapy with verteporfin for subretinal neovascularistion with Type 2A PFT were studied. All patients underwent visual acuity assessment with ETDRS letter acuity chart at 4 meters, slit lamp biomicroscopy, fundus fluorescein angiography and photography. Treatment protocol of TAP study was followed. The follow up schedule was every month for 3 months and then every 3 months thereafter until 12 months. Primary outcome measure was the change in visual acuity and secondary outcome measure was the mean treatment rate. Improvement was defined as ≥ 10 letters gain, stabilization as ± 10 letters and deterioration as > 10 letters loss. RESULTS: Twelve eyes of 7 patients received photodynamic therapy with verteporfin for SRNV with Type 2A PFT. Initial mean letter acuity was 25.4 and 23.4 at 12months (p = 0.7). At 12 months, one eye had > 10 letters gain, 2 eyes had ≥ 10 letters loss and 9 had stabilized vision (± 10 letters). The mean number of treatment was 2.6. Ten (83.3%) of 12 eyes had retinal pigment epithelial collateral change, observed at the end 12 months. CONCLUSION: Photodynamic therapy with verteporfin is effective in stabilization of vision in SRNV associated with type 2A PFT.